Sensitive data & IP
Clinical data, R&D and intellectual property protection.
Pharma
Sell into pharma accounts protecting clinical data, R&D and supply chains.
For providers selling data protection, identity and access, endpoint and supplier risk: CyberDre maps the pharma organisations whose GDPR accountability and NIS2 exposure make your offer a board-level subject.
The exposure
Sensitive data, R&D and supply chains under pressure.
Pharma organizations hold some of the most valuable data in the economy — clinical, R&D and IP — across sprawling supplier networks, all under GDPR and growing NIS2 exposure. That risk surface is your commercial opening.
Supply chain
Supplier and partner risk across complex manufacturing networks.
GDPR / NIS2
Data protection accountability and critical-sector exposure.
Their buying committee
The cross-functional pharma buying committee.
Offers that convert
- Data protection
- GDPR & NIS2 readiness
- Identity & access
- Endpoint security
- Supplier risk
Pharma FAQ
Questions pharma sellers ask.
Pharma organizations protect sensitive data, R&D, intellectual property and complex supply chains under GDPR and NIS2 exposure, creating demand for data protection, identity, endpoint and supplier-risk solutions.
Data protection, GDPR and NIS2 readiness, identity and access management, endpoint security and supplier risk. These convert because a pharma breach threatens intellectual property and clinical continuity at once — two losses the board can quantify without being educated first.
CISO, DPO, R&D IT, Compliance, Quality and Operations leaders.
Protect what matters most
Know which pharma accounts moved, and who decides there.
Book a free pipeline audit and discover which pharma organizations CyberDre can target for your offer.
Book My Free Pipeline Audit →